Longboard pharmaceuticals announces positive topline data from the pacific study, a phase 1b/2a clinical trial, for bexicaserin (lp352) in participants with developmental and epileptic encephalopathies (dees)

La jolla, calif.--(business wire)---- $lbph #dees--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline data from the pacific study evaluating bexicaserin (lp352), a potentially best-in-class and highly selective, oral, novel 5-ht2c receptor superagonist for seizures associated with a broad range of developmental and epileptic encephalopathies (dees). the pacif.
LBPH Ratings Summary
LBPH Quant Ranking